Endpoints
The primary endpoint of this study was to evaluate the incidence of CTLS in patients with high-grade B-cell lymphoma treated with a fractionated rituximab schedule. Secondary end-points were to report the incidence of LTLS and other adverse events of interest (e.g. infusion reactions), explore clinical risk factors related with CTLS and report progression-free survival (PFS) and overall survival (OS) of the whole cohort, by TLS / no TLS and IPI subgroups.